Supplementary Figure 8 from Maximizing the Efficacy of MAPK-Targeted Treatment in <i>PTEN</i><sup>LOF</sup><i>/BRAF</i><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition

PI3K pathway inhibition using PI3Kβi/PI3Kαi or PI3Kβi/IGF1Ri enhances the anti-proliferative effect of the BRAF/MEK inhibition regimen in PTEN^LOF/BRAF^MUT cell lines and shifts the response towards cell death A+B) Validation of BRAFi/MEKi activity in RVH-421 (A) and WM-266-4 (B) in the absence or presence of PI3Kβi/PI3Kαi or PI3Kβi/IGF1Ri using proliferation (upper panels; growth matrix highlighting percentages of proliferation inhibition relative to DMSO) or cell death assays (lower panels; fraction of PI-positive, dead cells). PI3Kβi=rac-KIN-193, PI3Kαi=BYL719, IGF1Ri=AEW541, BRAFi=LGX818, MEKi=MEK162